住院姑息治疗对造血干细胞移植后2周生活质量的影响:一项随机临床试验
这项非盲随机临床试验在160名接受自体/异基因造血干细胞移植的血液恶性肿瘤成人患者中,评估住院期间姑息治疗对患者和照护者报告结局的影响。结果显示,与标准移植治疗相比,姑息治疗组患者从基线到移植后2周的生活质量下降更小,抑郁、焦虑和症状负担增加更少;移植后3个月时生活质量更高、抑郁症状更少,但焦虑、疲乏和症状负担无显著差异。照护者仅抑郁增加更少,生活质量和焦虑无显著差异。
要点
- 住院姑息治疗可减轻造血干细胞移植患者2周时生活质量的下降幅度。
- 姑息治疗组在2周时抑郁、焦虑和症状负担的增加均少于标准治疗组。
- 移植后3个月时姑息治疗组生活质量更高、抑郁症状更少,但焦虑、疲乏和症状负担无显著差异。
核心结论
- 在接受造血干细胞移植的血液恶性肿瘤成人患者中,与标准移植治疗相比,住院姑息治疗使移植后2周生活质量下降更小。
- 需要进一步研究进行重复验证,并评估更长期结局和费用影响。
研究设计与样本
- 非盲随机临床试验,纳入160名接受自体/异基因造血干细胞移植的血液恶性肿瘤成人患者及其照护者94名。
- 研究于2014年8月至2016年1月在波士顿一家医院进行,随访于2016年5月完成。
- 干预组81名患者每周至少接受2次姑息治疗临床医生访视,聚焦躯体与心理症状管理;标准移植治疗组79名患者可按需接受姑息治疗。
主要发现
- 从基线到第2周,干预组生活质量均值从110.26降至95.46(变化-14.72),对照组从106.83降至85.42(变化-21.54),组间差异-6.82(95%CI -13.48至-0.16;P=0.045)。
- 从基线到第2周,干预组与对照组相比,抑郁增加更少(均值2.43 vs 3.94;均差1.52;95%CI 0.23-2.81;P=0.02),焦虑更低(均值-0.80 vs 1.12;均差1.92;95%CI 0.83-3.01;P<0.001),症状负担增加更少(均值17.35 vs 23.14;均差5.80;95%CI 0.49-11.10;P=0.03),疲乏无差异(均值-10.30 vs -13.65;均差-3.34;95%CI -7.25至0.56;P=0.09)。
- 移植后3个月,干预组与对照组相比生活质量评分更高(均值112.00 vs 106.66;均差5.34;95%CI 0.04-10.65;P=0.048),抑郁症状更少(均值3.49 vs 5.19;均差-1.70;95%CI -2.75至-0.65;P=0.002),焦虑、疲乏和症状负担无显著差异。
- 从基线到移植后2周,干预组患者照护者与对照组患者照护者相比,生活质量与焦虑无显著差异,但抑郁增加更少(均值0.25 vs 1.80;均差1.55;95%CI 0.14-2.96;P=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究在单一机构进行。
- 需要进一步研究进行重复验证,并评估更长期结局和费用影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: During hospitalization for hematopoietic stem cell transplantation (HCT), patients receive high-dose chemotherapy before transplantation and experience significant physical and psychological symptoms and poor quality of life (QOL). OBJECTIVE: To assess the effect of inpatient palliative care on patient- and caregiver-reported outcomes during hospitalization for HCT and 3 months after transplantation. DESIGN, SETTING, AND PARTICIPANTS: Nonblinded randomized clinical trial among 160 adults with hematologic malignancies undergoing autologous/allogeneic HCT and their caregivers (n = 94). The study was conducted from August 2014 to January 2016 in a Boston hospital; follow-up was completed in May 2016. INTERVENTIONS: Patients assigned to the intervention (n=81) were seen by palliative care clinicians at least twice a week during HCT hospitalization; the palliative intervention was focused on management of physical and psychological symptoms. Patients assigned to standard transplant care (n=79) could be seen by palliative care clinicians on request. MAIN OUTCOMES AND MEASURES: Primary: change in patient QOL from baseline to week 2; secondary: patient-assessed mood, fatigue, and symptom burden scores at baseline, 2 weeks, and 3 months after HCT and caregiver-assessed QOL and mood at baseline and 2 weeks after HCT. RESULTS: Among 160 enrolled patients (mean age, 60 [SD, 13.3] years; 91 women [56.9%]; median hospital stay, 21 days) and 94 caregivers, 157 (98.1%) and 89 (94.7%), respectively, completed 2-week follow-up, and 149 patients (93.1%) completed 3-month follow-up. Patients in the intervention group reported a smaller decrease in QOL from baseline to week 2 (mean baseline score, 110.26; week 2 score, 95.46; mean change, -14.72) compared with patients in the control group (mean baseline score, 106.83; week 2 score, 85.42; mean change, -21.54; difference between groups, -6.82; 95% CI, -13.48 to -0.16; P = .045). Among the secondary outcomes, from baseline to week 2, patients in the intervention group vs those in the control group had less increase in depression (mean, 2.43 vs 3.94; mean difference, 1.52; 95% CI, 0.23-2.81; P = .02), lower anxiety (mean, -0.80 vs 1.12; mean difference, 1.92; 95% CI, 0.83-3.01; P < .001), no difference in fatigue (mean, -10.30 vs -13.65; mean difference, -3.34; 95% CI, -7.25 to 0.56; P = .09), and less increase in symptom burden (mean, 17.35 vs 23.14; mean difference, 5.80; 95% CI, 0.49-11.10; P = .03). At 3 months after HCT, intervention patients vs control patients had higher QOL scores (mean, 112.00 vs 106.66; mean difference, 5.34; 95% CI, 0.04-10.65; P = .048) and less depression symptoms (mean, 3.49 vs 5.19; mean difference, -1.70; 95% CI, -2.75 to -0.65; P = .002) but no significant differences in anxiety, fatigue, or symptom burden. From baseline to week 2 after HCT, caregivers of patients in the intervention group vs caregivers of patients in the control group reported no significant differences in QOL or anxiety but had a smaller increase in depression (mean, 0.25 vs 1.80; mean difference, 1.55; 95% CI, 0.14-2.96; P = .03). CONCLUSIONS AND RELEVANCE: Among adults at a single institution undergoing HCT for hematologic malignancy, the use of inpatient palliative care compared with standard transplant care resulted in a smaller decrease in QOL 2 weeks after transplantation. Further research is needed for replication and to assess longer-term outcomes and cost implications. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02207322.
引用
- El-Jawahri A, LeBlanc T, VanDusen H, et al. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2016. PMID: 27893130. doi:10.1001/jama.2016.16786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。